Minimization in randomized clinical trials

Area of Science:

• Clinical Trial Design and Methodology
• Biostatistics
• Medical Research

Background:

• Randomized trials ensure treatment group comparability via random allocation, controlling for confounding factors.
• Imbalances in prognostic factors can occur despite random allocation, potentially biasing results.
• Balancing prognostic factors across treatment groups is preferred by trialists, regulatory agencies, and stakeholders.

Purpose of the Study:

• To compare the performance of minimization, a covariate-adaptive procedure, against completely random allocation and stratified blocked designs.
• To evaluate these allocation procedures based on operating characteristics, predictability, and achieved balance.
• To identify optimal scenarios for implementing minimization in clinical trials.

Main Methods:

• Comparison of minimization with completely random allocation and stratified blocked designs.
• Utilized individual patient data from two clinical trials (ovarian cancer, age-related macular degeneration).
• Analyzed operating characteristics using asymptotic and randomization tests, assessed predictability, and measured achieved balance.
• Investigated achieved balance in 50 actual trials using minimization.

Main Results:

• Minimization demonstrated superior balance in prognostic factors compared to completely random and stratified blocked designs.
• Covariate-adaptive procedures like minimization offer improved control over baseline imbalances.
• Minimization showed specific advantages in trials with numerous prognostic factors, multiple centers, or moderate sample sizes.

Conclusions:

• Minimization is an effective covariate-adaptive procedure for achieving balanced treatment groups in randomized trials.
• It is particularly valuable in complex trial settings, enhancing the reliability of treatment effect estimates.
• The study highlights the utility of minimization for improving clinical trial design and execution.